SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population based survey of urinary symptoms. J Urol 1993; 150: 859
  • 2
    Boyle P, Robertson C, Manski R et al. Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 2001; 58: 71722
  • 3
    Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 46670
  • 4
    Lepor H. Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 6519
  • 5
    Kallenberg F, Hossack TA, Woo HH. Long-term followup after electrocautery transurethral resection of the prostate for benign prostatic hyperplasia. Adv Urol 2011; 2011: doi:10.1155/2011/359478
  • 6
    Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol 2006; 13 (Suppl. 4): 19
  • 7
    Simpson LL. The neuroparalytic and hemaglutining activity of botulinum toxin. In Plenum Press ed., Neuropoisons: Their Pathophysiological Actions, New York, 1971: 30324
  • 8
    Chuang YC, Tu CH, Huang CC et al. Intraprostatic botulinum toxin type A injection relieves bladder outlet obstruction and induces prostate apoptosis. BMC Urol 2006; 6: 127
  • 9
    Pennefather JN, Lau WAK, Mitchelson F, Ventura S. The autonomic and sensory innervation of the smooth muscle of the prostate gland: a review of pharmacological and histological studies. J Auton Pharmacol 2000; 20: 93206
  • 10
    Lepor H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81 (Suppl. 1): 2933
  • 11
    Chartier-Kastler E, Mehnert U, Denys P, Giuliano F. Botulinum neurotoxin A for male urinary tract symptoms. Curr Opin Urol 2011; 21: 1321
  • 12
    Marchal C, Perez JE, Herrera B, Machuca FJ, Redondo M. The use of botulinum toxin in benign prostatic hyperplasia. Neurourol Urodyn 2012; 31: 8692
  • 13
    Cockett A, Aso Y, Denis L et al. Recommendation of the international consensus committee concerning: 1. Prostate symptom score and quality of life assessment. In Cockett ATK, Khoury S, Aso Y et al eds, Proceedings of the Second International Consultation on Benign Prostatic Hyperplasia (BPH), Paris, June 27–30, 1993, Jersey: Channel Island, Scientific Communication International, 1994: 5535
  • 14
    Watson V, Ryan M, Brown CT, Barnett G, Ellis BW, Emberton M. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 2004; 172: 23215
  • 15
    Hong SJ, Rayford W, Valiquette L, Emberton M. The importance of patient perception in the clinical assessment of benign prostatic hyperplasia and its management. BJU Int 2005; 95: 159
  • 16
    Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 54754
  • 17
    McVary KT, Roehrborn CG, Avins AL et al. AUA guideline on the management of benign prostatic hyperplasia (BPH). 2010. Available at: http://www.auanet.org/content/clinical-practice-guidelines/clinical-guidelines.cfm?sub=bph. Accessed 6 February 2012
  • 18
    Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 82230
  • 19
    Andersson K-E. Mode of action of α1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU Int 2000; 85: 128
  • 20
    Maria G, Brisinda G, Civello IM, Bentivoglio AR, Sganga G, Albanese A. Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study. Urology 2003; 62: 25965
  • 21
    Brisinda G, Cadeddu F, Vanella S, Mazzeo P, Marniga G, Maria G. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results. Urology 2009; 73: 904
  • 22
    Guercini F, Giannantoni A, Bard RL et al. Intraprostatic botulin toxin injection in patients with severe benign prostatic hyperplasia: a multicenter feasibility study. J Urol 2005; 173 (Suppl): 3767
  • 23
    Nikoobakht M, Daneshpajooh A, Ahmadi H et al. Intraprostatic botulinum toxin type A injection for treatment of benign prostatic hyperplasia: initial experience with Dysport. Scand J Urol Nephrol 2010; 44: 1517
  • 24
    Silva J, Pinto R, Carvalho T et al. Intraprostatic botulinum toxin type A injectionin patients with benign prostatic enlargement: duration of the effect of a single treatment. BMC Urol 2009; 9: 16
  • 25
    Park DS, Cho TW, Lee YK, Lee JH, Hong YK, Lee YT. Evaluation of short term clinical effects and presumptive mechanism of Botulinum toxin type A as a treatment modality of benign prostatic hyperplasia. Yonsei Med J 2006; 47: 70614
  • 26
    Kuo HC. Prostate botulinum toxin A injection – an alternative treatment for benign prostatic obstruction in poor surgical candidates. Urology 2005; 65: 670419
  • 27
    Chuang YC, Chiang CH, Yoshimura N et al. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia. BJU Int 2006; 98: 10337
  • 28
    Cam K, Akman Y, Kayikci A et al. Short-term subjective efficacy of doxazosin in predicting probability of prostatectomy in the management of benign prostatic hyperplasia in patients with severe symptoms. Int J Urol 2003; 10: 5826
  • 29
    Barkin J, Roehrborn CG, Siami P et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe BPH: 2-year data from the CombAT trial. BJU Int 2009; 103: 91926
  • 30
    Montorsi F, Henkel T, Geboers A et al. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study. Int J Clin Pract 2010; 64: 104251
  • 31
    Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: the Prostate Research on Behaviour and Education (PROBE) Survey. Int J Clin Pract 2008; 62: 1826
  • 32
    Lepor H. Phase III multicenter placebo-controlled study of tamsu- losin in benign prostatic hyperplasia. Urology 1998; 51: 892900
  • 33
    Michel MC, Mehlburger L, Bressel HU et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 1998; 1: 3325
  • 34
    Barry MJ, Williford WO, Chang Y et al. Benign prostatic hyperplasia specific healthy status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 17704
  • 35
    Chang HS, Park CH, Kim DK et al. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. Urology 2010; 75: 115661
  • 36
    Brooks SK. Effect of tamsulosin on AUA symptom score and BPH Impact Index as a function of symptpm severity in patients with benign prostatic hyperplasia. J Urol 1999; 161 (Suppl. 4): 267. [Abstract 1031]
  • 37
    Roehrborn CG, Siami P, Barkin J et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 12331
  • 38
    Desgrandchamps F, Droupy S, Irani J et al. Effect of dutasteride on the symptoms of benign prostatic hyperplasia, and patient quality of life and discomfort, in clinical practice. BJU Int 2006; 98: 838
  • 39
    Jiménez-Cruz F. Identifying patients with lower urinarytract symptoms/benign prostatic hyperplasia (LUTS/BPH) at risk for progression. Eur Urol Suppl 2003; 2: 612
  • 40
    O'Leary M. Achieving the total approach in lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) management. Eur Urol Suppl 2003; 2: 2533
  • 41
    Silva J, Pinto R, Carvalho T et al. Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function. BJU Int 2011; 107: 19504
  • 42
    Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 63749
  • 43
    Chuang YC, Huang CC, Kang HY et al. Novel action of botulinum toxin on the stromal and epithelial components of the prostate gland. J Urol 2006; 175: 115863
  • 44
    Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006; 60: 115765